The crystal structure is shown in the gure. Tables 1 and  2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.
. 
Source of material
The title compound was synthesized according to a reported procedure [5] . A mixture of 3,5-cyclohexanedione (10 mmol), 3-tri uoromethylbenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1mmol) in ethanol (100 mL) was re uxed for 2-3 h and then cooled to room temperature. After ltering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under a vacuum.
Experimental details
Carbon-bound H atoms were placed in calculated positions (C-H 0.95 Å) and included using the riding model approximation, with U iso (H) set to 1.2Ueq(C). The H atoms of the amine were idealized and were included in the re nement as riding atoms, with U iso (H) set to 1.2Ueq(N). The F atoms of the CF 3 group are disordered over two positions.
Discussion
Several derivatives of the pyran or fused pyran ring systems are endowed with di erent types of biological activities [1, 2] . It has been reported that pyran derivatives exhibit antimicrobial activity, growth stimulating e ects, antifungal and plant growth regulation e ects, antitumor activity, central nervous system (CNS) activity and hypotensive e ect [3] . Moreover pyran derivatives are well known for antihistaminic activity, platelet antiaggregating activity and local anaesthetic activity, antiallergenic e ect, antidepressant e ect and as antiproliferation agents [4] . In the crystal structure of the title compound, the 4H-pyran ring is nearly planar [maximum deviation = 0.0665 Å] and the adjacent ring shows a typical folding of the saturated C 3 H 6 moiety. The 4H-pyran ring is almost perpendicular to the substituated phenyl group [dihedral angle = 87.8°].
